Patents Examined by James H. Alstrum-Acevedo
  • GrB-EHinhibitory peptides
    Patent number: 10793598
    Abstract: Fusion peptides and methods of inhibiting GrB-EHITSN or a fragment thereof are provided. The fusion peptides include an NPF peptide and a cell-permeable peptide operably connected thereto. Fusion peptides and methods of inhibiting activity of GrB-EHITSN or fragment thereof are provided. An aspect includes a fusion peptide comprising an isolated NPF peptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 2 and a cell-permeable peptide operably connected to the isolated NPF peptide, wherein the fusion peptide inhibits activity of GrB-EHITSN or a fragment thereof.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 6, 2020
    Assignee: Rush University Medical Center
    Inventors: Sanda Predescu, Dan Predescu
  • Anthelmintic depsipeptide compounds
    Patent number: 10793604
    Abstract: The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: October 6, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Loic Le Hir de Fallois, Greg Pacofsky, Alan Long, Charles Meng, Hyoung Ik Lee, Cyprian O. Ogbu
  • Discrete PEG constructs
    Patent number: 10786497
    Abstract: Disclosed are linear discrete PEG constructs, which can be created and produced in a precise and reproducible way. Key to being able to do these things, where x in the discrete PEGx can vary from about 2 to about 64, is that the processes used to make each linear portion is controlled to give essentially one oligomer/one compound. Having a variable length linear discrete PEG construct that is (a) primarily an linear discrete PEG construct with diagnostic or therapeutic groups attached along a chain of attachment cores, which is attached to a preferential locator; (b) is an m-discrete PEG as the terminal construct on the linear portion, and “hidden”; (c or linear discrete PEG with a terminus group that can be either negatively or positively charged, or neutral; and any of the discrete PEG portions can be designed to be cleaved after entering the cell.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: September 29, 2020
    Assignee: EquIP, LLC
    Inventor: Paul D. Davis
  • Cytotoxic peptides and conjugates thereof
    Patent number: 10787480
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
    Patent number: 10774110
    Abstract: A compound of Formula (I), and its analogs are provided. Compositions that include Formula I can be used to inhibit human equilibrative nucleoside transporter 1, increase adenosine signaling and produce effects that include increasing antiviral activity, increasing antiparasitic activity, increasing alcohol tolerance, decreasing pain protecting from ischemia as well as many other conditions.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: September 15, 2020
    Assignee: The Johns Hopkins University
    Inventors: Jun Liu, Jingxin Wang, Zhaoli Sun, Sam Hong
  • Detection of platelet-derived shed CD31
    Patent number: 10775387
    Abstract: The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: September 15, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE PARIS, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Opioid peptide
    Patent number: 10774111
    Abstract: The present invention relates to an opioid peptide represented by general formula TyrGlyGly-X1-X2-X3-X4, wherein: X1 is represented by Thr or Glu; X1 is represented by Gly or Thr or Ala; X3 is represented by Ala or Val or Gly or Glu; and X4 is represented by His or Gln or Thr or SEQ ID NO:1, or HisTyr or GlnTyr or ThrTyr. The invention also relates to pharmaceutical and food compositions comprising the peptide and to the use of the same for analgesic purposes, and/or for providing a feeling of satiety to a subject.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: September 15, 2020
    Assignees: EMBRAPA-EMPRESA BRASILEIRA DE PESQUISA AGROPECUARIA, FUNDAÇÃO UNIVERSIDADE DE BRASÍLIA—FUB—UNB
    Inventors: Carlos Bloch, Jr., Felipe Vinecky, Karla Graziella Moreira, Márcia Renata Mortari
  • Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphangiogenesis-dependent diseases
    Patent number: 10774131
    Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumori-genic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: September 15, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Aleksander S. Popel, Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz
  • Composition for treating apoplexy through nasal administration
    Patent number: 10772827
    Abstract: The present invention relates to a nasal administration composition for preventing or treating ischemic cerebrovascular disease, containing a Fas targeting peptide (FTP). When using the pharmaceutical composition or kit of the present invention, a drug can be effectively delivered to brain tissue and the ischemic cerebrovascular disease of a subject can be effectively prevented or treated.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: September 15, 2020
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Sang-Kyung Lee, Irfan Ullah, Kun Ho Chung, Jung Ju Oh, Min Hyung Lee, Priti Kumar
  • ERG targeted therapy
    Patent number: 10774122
    Abstract: The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 15, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Arul Chinnaiyan, Xiaoju Wang
  • Peptides that stimulate subcutaneous adipogenesis
    Patent number: 10766927
    Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis and uses thereof are provided.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: September 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Eva A. Turley, Seyed Bahram Bahrami, Mina J. Bissell
  • Angiotensin II alone or in combination for the treatment of hypotension
    Patent number: 10765722
    Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: September 8, 2020
    Assignee: The George Washington University a Congressionally Chartered Not-for-Profit Corporation
    Inventor: Lakhmir S. Chawla
  • Fast-off rate serum albumin binding fibronectin type III domains
    Patent number: 10766946
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 8, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
  • Chimeric inhibitor molecules of complement activation
    Patent number: 10752661
    Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: August 25, 2020
    Assignee: Omeros Corporation
    Inventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
  • Lipidated peptides as neuroprotective agents
    Patent number: 10751390
    Abstract: Lipidated neuropeptides PrRP31, PrRP20, containing C14 to C16 fatty acid, and their analogs, wherein a sequence of IRPVGRF-NH2 at the C-terminus is variable in the site of isoleucine, valine and phenylalanine; said fatty acid is bound in position 1 or 11 for PrRP31 or its analog and in position 1 or 7 for PrRP20 or its analog; the bond comprises an amide bond between an amino acid having at least one free NH2 group and a carboxylic group of the fatty acid and alternatively includes also a binding through arm X2, which is a hydrophilic linker selected from a group comprising ?-alanine, ?-aminobutyric acid or ?-glutamic acid; for use in the treatment and prevention of diseases, which are Alzheimer's disease (AD), Parkinson's disease (PD), cognitive impairment no dementia (CIND), brain trauma, and neurodegenerative changes and disorders.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: August 25, 2020
    Assignee: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I.
    Inventors: Lenka Maletinska, Blanka Zelezna, Miroslava Blechova, Andrea Spolcova, Barbora Mikulaskova, Jaroslav Kunes, Stepan Strnad
  • Antimicrobial peptides derived from hepatitis B virus core protein arginine-rich domain
    Patent number: 10752657
    Abstract: A pharmaceutical composition comprising: (a) an isolated peptide, wherein the peptide includes three or four arginine-rich domains (ARDs) from the carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an anti-microbial activity; and (b) a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 25, 2020
    Assignee: Academia Sinica
    Inventors: Chiaho Shih, Heng-Li Chen, Pei-Yi Su
  • Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
    Patent number: 10751424
    Abstract: The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also to methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier cargo complex. The present invention also provides methods of application and use of this inventive polymeric carrier molecule and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment of such diseases.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: August 25, 2020
    Assignee: CureVac AG
    Inventors: Patrick Baumhof, Thomas Schlake
  • Peptides and nanoparticles for intracellular delivery of molecules
    Patent number: 10745440
    Abstract: The present invention pertains to peptides and peptide-containing complexes/nanoparticles that are useful for stabilizing and delivering cargo molecules such as nucleic acids.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 18, 2020
    Assignee: Aadigen, LLC
    Inventors: Gilles Divita, Neil Desai
  • Methods and compositions for the prevention and treatment of disease
    Patent number: 10744178
    Abstract: The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: August 18, 2020
    Assignee: Stealth BioTherapeutics Corp
    Inventor: D. Travis Wilson
  • Therapy and kit for the prevention and treatment of cystic fibrosis
    Patent number: 10744180
    Abstract: Compositions, kits and methods for preventing or treating cystic fibrosis are provided, which include the use of a peptidomimetic that inhibits the interaction between CAL and mutant CFTR proteins.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 18, 2020
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Dean R. Madden, Nicholas P. Gill, Carrie Ann Davison, Mark R. Spaller